147 related articles for article (PubMed ID: 35151352)
21. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
22. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
23. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
24. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
25. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.
Geller G; Laskin J; Cheung WY; Ho C
Thyroid Res; 2017; 10():6. PubMed ID: 28932277
[TBL] [Abstract][Full Text] [Related]
26. Four cases of medullary thyroid carcinomas associated with multiple endocrine neoplasia 2B with rearranged during transfection codon M918T mutation in the same family.
Tanaka A; Uemura H; Morimoto C; Nishimura A; Yoshii Y; Masui T; Ota I; Kitahara T
Mol Clin Oncol; 2022 Jan; 16(1):13. PubMed ID: 34881033
[TBL] [Abstract][Full Text] [Related]
27. Role of vandetanib in the management of medullary thyroid cancer.
Brassard M; Rondeau G
Biologics; 2012; 6():59-66. PubMed ID: 22500115
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
29. Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study.
Masaki C; Sugino K; Tanizawa Y; Nakamura K; Okada Y; Cai Z; Okamoto T
Drugs Real World Outcomes; 2023 Mar; 10(1):145-158. PubMed ID: 36527599
[TBL] [Abstract][Full Text] [Related]
30. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
31. Completeness of
Mathiesen JS; Kroustrup JP; Vestergaard P; Stochholm K; Poulsen PL; Rasmussen ÅK; Feldt-Rasmussen U; Schytte S; Londero SC; Pedersen HB; Hahn CH; Bentzen J; Möller S; Gaustadnes M; Rossing M; Nielsen FC; Brixen K; Frederiksen AL; Godballe C;
Clin Epidemiol; 2019; 11():93-99. PubMed ID: 30666164
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness Outcomes in Patients With Recurrent or Refractory Head and Neck Cancers: Retrospective Analysis of Data From a Community Oncology Database.
Fisher MD; Fernandes AW; Olufade TO; Miller PJ; Walker MS; Fenton M
Clin Ther; 2018 Sep; 40(9):1522-1537. PubMed ID: 30150077
[TBL] [Abstract][Full Text] [Related]
33. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double
Romei C; Casella F; Tacito A; Bottici V; Valerio L; Viola D; Cappagli V; Matrone A; Ciampi R; Piaggi P; Ugolini C; Torregrossa L; Basolo F; Materazzi G; Vitti P; Elisei R
J Med Genet; 2016 Nov; 53(11):729-734. PubMed ID: 27468888
[TBL] [Abstract][Full Text] [Related]
34. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
35. Innovation and Precision Medicine Applied to a Medullary Thyroid Cancer: A Clinical Case.
Guedes H; Leão I; Soares A; Basto R; Joaquim A
Cureus; 2023 Jun; 15(6):e40107. PubMed ID: 37425604
[TBL] [Abstract][Full Text] [Related]
36. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
Zanotti G; Hunger M; Perkins JJ; Horblyuk R; Martin M
BMC Cancer; 2017 Jun; 17(1):393. PubMed ID: 28578656
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
40. Pediatric Medullary Thyroid Carcinoma.
Starenki D; Park JI
J Pediatr Oncol; 2015; 3(2):29-37. PubMed ID: 27014708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
